Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed.
Investor's Business Daily on MSN2d
Novartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedNovartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...
Amgen's olpasiran and pelacarsen from Novartis. Lilly is also testing muvalaplin, the only oral treatment for LP(a) in ...
Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision ...
After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.
The NFL named Novartis as its first-in-category corporate pharmaceutical partner. Together, the two organizations will work to promote healthy choices and making active decisions in regard to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback